-- 米国の新築住宅販売件数は、3月に年率換算で68万2000戸となり、2月の63万5000戸から増加しました。これは、ブルームバーグが東部時間午前7時40分時点でまとめた調査で予測されていた65万2000戸を大きく上回るものです。 住宅販売件数は、2025年3月と比較して3.3%増加しました。 販売可能な住宅在庫は、前月の48万3000戸から0.4%減の48万1000戸となり、前年同月比では4.6%減少しました。 販売価格の中央値は、3月の40万9000ドルから38万7400ドルに下落し、前年同月の41万2900ドルを下回りました。 米国商務省が発表する月次新築住宅販売報告書は、契約締結時点での新築一戸建て住宅の販売件数を計測したものです。 この報告書には、販売可能な新築住宅の戸数と販売価格の中央値が含まれています。好調な数値は、住宅ローン貸付業者、住宅建設業者、および関連する消費財企業にとって好ましい兆候である。
Related Articles
American Electric Power CEO Says Speed to Market Key Issue in Load Connection
American Electric Power (AEP) CEO Bill Fehrman said Tuesday that speed to market is the main issue in efficiently connecting energy load to generation.In a Q1 earnings call, Fehrman said that, in particular, the performance and stakeholder approval process of PJM, the US mid-Atlantic grid operator, represents a major challenge."The current state of PJM's performance and stakeholder approval process does not give me great confidence that these issues will be resolved any time soon," Fehrman said on the call."In fact, if something is not done now, I expect we could still be having these same conversations in 10 years," he added.Expanding and strengthening the grid will ensure new generation resources can connect quickly, reliably, and affordably to serve the growing load, the CEO said.Price: $137.27, Change: $+2.61, Percent Change: +1.94%
MGE Energy Q1 Earnings, Revenue Rise
MGE Energy (MGEE) reported Q1 earnings Tuesday of $1.32 per diluted share, up from $1.14 a year earlier.One analyst polled by FactSet expected $1.13.Revenue for the three months ended March 31 was $242.7 million, up from $219 million a year earlier.Price: $80.48, Change: $+0.36, Percent Change: +0.46%
Research Alert: CFRA Lowers Rating On Shares Of Pfizer Inc. To Hold From Buy
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our target to $28 from $31, 9.4x our 2027 EPS estimate, below PFE's historical forward P/E average. We keep our 2026 EPS view at $2.99 and our 2027 EPS at $2.97. PFE delivered solid top- and bottom-line Q1 results today that exceeded expectations while demonstrating continued progress in its post-Covid transition strategy. While we continue to think that shares are trading at a discount, as the company's main focus in the next year is on AI integration, and a new transformative M&A is not a key priority, we see limited catalysts to drive meaningful upside potential. We think PFE is aiming to maximize value from launched and acquired products with particular focus on key areas: oncology, obesity/metabolic disease, and vaccines. PFE remains committed to maintaining its dividend, continuing productivity initiatives ($7.2B cost savings target), and pursuing targeted business development (with $7B capacity) but we do not expect PFE executing share buybacks to support the share price in the near term.